过程几十年的付出，科学技术家们在对於四种恶意癌症的KRAS转变多方面现已拿得了多向进展情况:After decades of efforts, scientists have made progress into targeting KRAS mutations in several malignancies.在196八年, Ha-Ras 和 Ki-Ras反转录病原体转变成表观遗传被发掘，这些食品对应着的人類RAS族氏HRAS和KRAS于1982年被发掘.In 1967, Ha-Ras and Ki-Ras retroviral transforming genes were discovered.Their human counterparts,Ha-Ras and Ki-Ras ,were discovered in 1982.KRAS 与癌症的干系于1983年被再次形容，一些年KRAS 变动在癌症中就有多选题现况。变动的KRAS被不间断性重置，并致使不间断的河流下游数据传导电流和淋巴肿瘤产生。The relationship between KRAS and lung cancer was described in 1984,KRAS mutation in lung cancer has progressed.Mutant KRAS is constitutively activated and leads to persistent downstream signalling and oncogenesis.在201四年随对KRAS生态学学的理解挖深和制剂设定技能的版本更新，科学性家们在GDP配合的突变的型KRAS G12C 蛋清中看见了半胱氨酸制剂配合袋。In 2013 improved understanding of KRAS biology and newer drug designing technologies led to crucial discovery of a cysteins drug binding pocket in GDP-bound mutant KRAS G12C protein.在202半年，地理生理学家们胜利设计出中医变动型KRAS G12C 的共价缓和剂。202半年4月，Sotorasib拥有FDA审批权，用以的治疗KRAS G12C变动的NSCLC，这便是第1 个获准的KRAS G12C缓和剂，近年来再有一些口服药真正研发部门中。In 2021,covalent inhibitors that block mutant KRAS G12C were successfully developed.In May 2021 the US FDA granted accelerated approval to Sotorasib(1st KRAS G12C inhibitor)，for the treatment of adults with advanced NSCLC with KRAS G12C mutation.Sotorasib was the first KRAS G12C inhibitor to be approved，with several more in the pipeline。
相关内容欧宝体育app
关于欧宝体育app
